http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019314528-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d0edcdfa53bbfe33de73ce80a119e21 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate | 2019-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc3ea6d5412e276cf3c033bd7bbd3cdc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37ae64a2e5a8c4be0a90a7002830fc3d |
| publicationDate | 2019-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2019314528-A1 |
| titleOfInvention | Targeted therapeutics |
| abstract | The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety. |
| priorityDate | 2013-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1052.